Early bleed detection Target hospitals and vascular/interventional centers performing high-risk endovascular procedures such as TAVR and large bore access, highlighting the Early Bird Bleed Monitoring System as a standard-of-care enhancement to reduce bleeding complications and post-procedure care costs.

Clinical trial expansion Leverage SAFE-MCS trial momentum to engage sites and investigators for additional enrollment, presenting real-world outcomes and ROI from reduced bleeding events to accelerate adoption and reimbursement discussions.

FDA approved value Emphasize FDA-cleared status and proven usage with over a thousand treated patients to build credibility with procurement and clinical leaders, pairing with case studies demonstrating improved patient safety and workflow efficiency.

Strategic partnerships Propose collaborations with vascular access sheath manufacturers, interventional device companies, and health systems to embed the Early Bird technology into existing product ecosystems, creating integrated solutions and bundled offerings.

Market readiness Highlight scalable tech stack and cloud-based monitoring to support remote or centralized monitoring programs, appealing to hospitals pursuing digital health modernization, data analytics, and value-based care initiatives.